-- Halozyme (HALO) said Wednesday its Hypercon unit entered into an agreement with Oruka Therapeutics (ORKA) on exclusive rights to use a specialized microparticle drug platform for an experimental psoriasis treatment and up to one additional target.
The transaction requires an immediate upfront payment, potential future milestone payments, and ongoing mid-single-digit royalties based on future commercial product sales, the company said.
The system allows biologic drugs to be more highly concentrated, shrinking the required injection volume and making dosing easier, Halozyme said.
Price: $66.17, Change: $+0.30, Percent Change: +0.46%